middl
east
respiratori
syndrom
mer
highli
lethal
respiratori
diseas
caus
novel
singlestrand
positivesens
rna
betacoronaviru
merscov
dromedari
camel
host
merscov
implic
direct
indirect
transmiss
human
be
although
exact
mode
transmiss
unknown
viru
fi
rst
isol
patient
die
sever
respiratori
ill
june
jeddah
saudi
arabia
may
laboratoryconfi
rmed
case
death
mortal
report
communityacquir
hospitalacquir
case
report
littl
humantohuman
transmiss
report
commun
although
case
mer
occur
saudi
arabia
unit
arab
emir
case
report
europ
usa
asia
peopl
travel
middl
east
contact
clinic
featur
mer
rang
asymptomat
mild
diseas
acut
respiratori
distress
syndrom
multiorgan
failur
result
death
especi
individu
underli
comorbid
specifi
c
drug
treatment
exist
mer
infect
prevent
control
measur
crucial
prevent
spread
healthcar
facil
merscov
continu
endem
lowlevel
public
health
threat
howev
viru
could
mutat
increas
interhuman
transmiss
increas
pandem
potenti
fi
rst
report
middl
east
respiratori
syndrom
mer
describ
patient
die
sever
respiratori
ill
hospit
jeddah
saudi
arabia
june
previous
unrecognis
coronaviru
merscov
isol
patient
similar
sever
acut
respiratori
syndrom
coronaviru
sarscov
caus
epidem
viru
initi
design
human
coronavirusemc
renam
merscov
global
consensu
genom
structur
merscov
delin
dipeptidylpeptidas
also
known
identifi
ed
hostcel
receptor
cell
entri
revers
genet
enabl
viru
genom
studi
molecular
diagnost
test
quickli
develop
high
mortal
rate
familybas
hospitalbas
outbreak
especi
patient
comorbid
diabet
renal
failur
along
respiratori
droplet
rout
transmiss
evok
global
concern
intens
discuss
media
number
report
mer
case
spike
hospitalbas
cluster
outbreak
spring
case
still
detect
throughout
year
merscov
deem
seriou
public
health
epidem
threat
million
pilgrim
countri
converg
saudi
arabia
year
hajj
umrah
pilgrimag
fortun
mer
case
associ
hajj
pilgrimag
seminar
review
mer
epidemiolog
virolog
clinic
manifest
pathogenesi
diagnosi
case
manag
treatment
prophylact
intervent
includ
likelihood
widespread
outbreak
epidem
spread
outbreak
involv
patient
april
zarqa
jordan
sinc
case
identifi
ed
across
arabian
peninsula
asia
europ
africa
usa
fi
gure
patient
report
outsid
middl
east
histori
recent
travel
arabian
peninsula
close
contact
primari
case
saudi
arabia
report
case
case
death
mortal
may
sever
proactiv
global
surveil
inform
system
relat
mer
guidelin
prevent
treatment
infect
control
updat
regularli
us
center
diseas
control
prevent
saudi
ministri
health
european
centr
diseas
prevent
control
public
health
england
appendix
surveil
intensifi
ed
time
especi
healthcar
commun
outbreak
becom
clear
infect
patient
asymptomat
acut
febril
ill
upper
respiratori
tract
diseas
coronavirus
larg
kb
singlestrand
positivesens
rna
virus
fi
gure
enter
host
cell
merscov
attach
receptor
dipeptidyl
peptidas
proteas
cleavag
protein
requir
viruscel
fusion
releas
genom
rna
cytoplasm
viral
rna
transcript
replic
occur
doubl
membran
vesicl
membran
structur
deriv
endo
plasmic
reticulum
transcript
seven
subgenom
mrna
occur
via
negativestrand
subgenom
rna
intermedi
subgenom
rna
cotermin
nest
join
common
leader
encod
end
genom
viral
rna
encapsid
fi
gure
accessori
protein
requir
viru
viabil
interspers
throughout
structur
gene
might
interfer
innat
immun
respons
infect
anim
merscov
fi
diff
erent
accessori
protein
sarscov
eight
diff
erent
accessori
protein
share
sequenc
similar
diff
erenc
presum
diff
erent
eff
ect
induct
signal
type
interferon
could
explain
merscov
sensit
interferon
sarscov
diff
erenc
interferon
sensit
implic
treatment
type
interferon
use
treat
patient
infect
sarscov
merscov
coronavirus
high
rate
mutat
recombin
propens
cross
host
speci
although
properti
clearli
shown
spread
sarscov
chines
horsesho
bat
human
popul
epidem
coronavirus
bovin
coronaviru
felin
coronavirusii
canin
coronavirusii
transmiss
gastroenter
viru
swine
viru
close
relat
consist
crossspeci
transmiss
abil
adapt
new
environ
rais
concern
merscov
would
gain
virul
enhanc
abil
transmit
person
person
occur
merscov
sarscov
bind
larg
ectopeptidas
angiotensinconvert
enzym
respect
enter
cell
bind
hostcel
receptor
major
determin
pathogenesi
sinc
infect
occur
absenc
sarscov
probabl
origin
bat
adapt
nonbat
variant
angiotensinconvert
enzym
cross
speci
infect
human
be
chang
surfac
glycoprotein
enhanc
bind
human
receptor
merscov
mutat
much
transmiss
human
popul
singl
mutat
posit
surfac
protein
consist
detect
human
isol
aminoacid
locat
region
protein
involv
fusion
hostcel
membran
bind
contrast
sarscov
merscov
bind
sever
speci
thu
nonhuman
primat
rabbit
goat
sheep
hors
among
anim
thought
suscept
infect
addit
camel
human
be
diff
erenc
role
surfac
glycoprotein
mutat
viru
adapt
new
popul
probabl
result
subtl
diff
erenc
mechan
viru
entri
coronaviru
entri
involv
bind
receptor
subsequ
releas
fusion
peptid
rel
import
compon
diff
erent
sarscov
merscov
infect
understand
rel
role
receptor
bind
proteas
action
enabl
predict
whether
specifi
c
zoonot
coronavirus
infect
human
be
likelihood
adapt
sever
form
mer
caus
acut
highli
lethal
pneumonia
renal
dysfunct
failur
common
patient
could
consequ
either
hypox
damag
direct
infect
kidney
latter
possibl
express
high
level
kidney
analysi
patient
tissu
sampl
need
greater
understand
site
infect
unfortun
tissu
sampl
avail
larg
cultur
religi
reason
much
understand
pathogenesi
come
studi
experiment
infect
anim
sever
anim
experiment
infect
merscov
includ
macaqu
marmoset
camel
macaqu
develop
mild
clinic
diseas
evid
infl
ammatori
cell
infi
ltration
radiolog
examin
make
use
model
nonleth
mer
contrast
infect
marmoset
develop
sever
interstiti
pneumonia
neutrophil
macrophag
infi
ltration
alveolar
oedema
report
infect
lung
tissu
infect
marmoset
use
model
sever
mer
anim
readili
avail
limit
util
anoth
studi
three
camel
experiment
infect
merscov
develop
mild
rhiniti
system
diseas
viru
shed
sever
day
suggest
cameltocamel
cameltoperson
spread
contribut
ongo
mer
outbreak
small
rodent
model
would
use
mice
suscept
merscov
mice
sensitis
merscov
infect
adenovirusexpress
human
advantag
approach
strain
mous
made
suscept
merscov
thu
wherea
transduc
immunocompet
mice
develop
mild
clinic
diseas
mice
defi
cient
type
interferon
signal
develop
clinic
diseas
extens
patholog
chang
lung
like
infect
macaqu
mice
use
vaccin
antiviru
studi
mice
transgen
human
develop
sever
clinic
diseas
merscov
challeng
mice
also
develop
enceph
compromis
util
littl
known
constitut
protect
immun
respons
patient
recov
base
studi
coronavirus
includ
sarscov
coordin
innat
adapt
immun
respons
need
merscov
elicit
attenu
innat
immun
respons
delay
proinfl
ammatori
cytokin
induct
cell
cultur
vivo
could
contribut
dysregul
immun
respons
similar
fi
nding
report
patient
sar
ineff
ectual
bcell
tcell
respons
prolong
cytokin
express
detect
patient
sever
diseas
wherea
rapid
shutoff
innat
immun
respons
potent
antisarscov
antibodi
respons
report
recov
patient
antisarscov
antibodi
respons
wane
undetect
year
infect
wherea
tcell
respons
could
still
detect
thu
vaccin
result
antibodi
respons
probabl
use
short
term
might
provid
longterm
protect
merscov
exact
sourc
mode
transmiss
merscov
human
be
unknown
initi
investig
suggest
merscov
origin
bat
sequenc
relat
merscov
found
sever
bat
speci
studi
support
bat
sourc
show
bat
coronaviru
tylonycteri
bat
coronaviru
merscov
use
human
bat
hostcel
receptor
howev
merscov
never
isol
bat
whether
direct
indirect
transmiss
bat
peopl
import
remain
unknown
sever
anim
speci
arabian
peninsula
assess
serolog
evid
merscov
infect
serolog
assay
improv
sensit
specifi
citi
increas
earli
studi
dromedari
camel
camelu
dromedariu
oman
canari
island
spain
posit
antimerscov
antibodi
subsequ
studi
confi
rmed
high
rate
seroposit
camel
arabian
peninsula
also
show
evid
infect
cow
goat
sheep
one
key
question
whether
merscov
newli
emerg
camel
human
popul
whether
infect
present
mani
year
detect
retrospect
analysi
store
human
sampl
obtain
blood
donor
abattoir
worker
saudi
arabia
show
evid
merscov
seroreact
contrast
antimerscov
antibodi
detect
archiv
serum
sampl
dromedari
camel
obtain
saudi
arabia
unit
arab
emir
furthermor
mani
camel
saudi
arabia
import
east
africa
addit
studi
show
serum
sampl
camel
east
west
north
africa
posit
merscov
earli
indic
widespread
circul
merscov
camel
popul
mani
year
transmiss
camel
link
human
merscov
infect
fi
gure
although
patient
histori
camel
exposur
transmiss
ineffi
cient
howev
interpret
lack
obviou
exposur
might
confound
less
direct
exposur
exampl
patient
might
expos
infecti
viru
consumpt
unpasteuris
camel
milk
uncommon
saudi
arabia
ident
nearli
ident
virus
isol
geograph
link
infect
camel
patient
interpret
type
studi
complic
fact
rna
virus
infect
host
includ
merscovinfect
dromedari
camel
consist
swarm
close
relat
rna
molecul
quasispeci
transmiss
new
host
one
member
rna
viru
swarm
transmit
make
diffi
cult
isol
exact
viru
donor
recipi
high
proport
adult
camel
antimerscov
seroposit
high
antibodi
titr
individu
anim
suggest
infect
occur
young
age
frequent
boost
howev
conclus
disput
sinc
lack
contact
camel
human
case
rais
possibl
transmiss
primarili
persontoperson
anoth
intermedi
host
camel
infect
result
persontocamel
transmiss
addit
intermedi
host
might
involv
coronaviru
relat
merscov
isol
european
hedgehog
erinaceu
europaeu
togeth
result
suggest
although
mani
detail
cameltoperson
transmiss
unclear
transmiss
camel
peopl
confi
rmed
zoonot
sourc
human
infect
support
hypothesi
although
seropreval
gener
popul
camel
shepherd
slaughterhous
worker
merscovantibodi
posit
analys
human
popul
contact
camel
horn
africa
sourc
mani
camel
saudi
arabia
might
identifi
seroposit
individu
other
succumb
infect
although
mer
case
report
throughout
year
diseas
season
fi
rst
mer
case
identifi
ed
april
june
follow
case
april
may
similar
increas
april
may
small
peak
case
also
occur
septemb
novemb
increas
march
may
might
refl
ect
part
transmiss
newli
infect
young
camel
increas
mer
case
april
may
saudi
arabia
mainli
attribut
breach
infect
control
improv
report
high
degre
awar
widespread
screen
humantohuman
transmiss
merscov
confi
rmed
epidemiolog
genom
studi
case
associ
hospit
household
mer
outbreak
hospitalbas
outbreak
occur
april
may
alhasa
eastern
provinc
saudi
arabia
patient
receiv
haemodialysi
intens
care
unit
infect
singl
clade
viru
mortal
rate
spread
assum
larg
occur
via
larg
droplet
contact
although
possibl
airborn
fomit
transmiss
exclud
infect
result
persontoperson
spread
emphasis
import
appropri
contact
droplet
precaut
prevent
transmiss
patient
healthcar
worker
famili
member
persontoperson
spread
healthcar
facil
also
implic
merscov
outbreak
jeddah
saudi
arabia
patient
initi
consid
primari
case
investig
found
expos
merscovinfect
patient
gener
healthcar
facil
merscov
isol
singl
outbreak
close
relat
genom
data
consist
humantohuman
spread
accompani
period
reintroduct
viru
human
popul
r
merscov
gener
estim
less
substanti
less
associ
epidem
potenti
make
sustain
transmiss
viru
unlik
unless
mutat
comparison
r
sarscov
consist
sustain
transmiss
sar
epidem
seriou
symptomat
diseas
occur
often
patient
comorbid
diabet
renal
failur
underli
immunosuppress
howev
patient
without
underli
diseas
also
infect
although
develop
asymptomat
mild
clinic
diseas
merscov
transmiss
requir
close
contact
infect
patient
suscept
individu
even
condit
littl
transmiss
document
drosten
colleagu
show
transmiss
rate
patient
household
contact
roughli
one
infect
contact
develop
subclin
diseas
suggest
number
infect
saudi
arabia
countri
arabian
peninsula
africa
much
greater
report
lend
support
eff
ort
increas
surveil
countri
phylogeni
evolut
merscov
studi
whole
genom
sequenc
sampl
sever
geograph
region
appendix
one
instanc
four
diff
erent
merscov
phylogenet
clade
identifi
ed
patient
saudi
arabia
septemb
may
howev
end
observ
period
three
clade
longer
circul
consist
r
less
furthermor
extent
diff
erenc
genet
distinct
lineag
make
unlik
infect
result
singl
continu
chain
humantohuman
transmiss
clinic
manifest
merscov
infect
rang
asymptomat
infect
sever
pneumonia
acut
respiratori
distress
syndrom
septic
shock
multiorgan
failur
result
death
contrast
sar
tabl
patient
mer
least
one
comorbid
ill
patient
die
like
underli
condit
patient
die
vs
recov
asymptomat
patient
p
index
sporad
case
fi
rst
wave
older
median
age
year
vs
year
p
like
sever
diseas
requir
admiss
hospit
vs
p
secondari
case
secondari
case
mild
diseas
asymptomat
infect
basi
data
relat
humantohuman
transmiss
sever
cluster
incub
period
estim
day
could
long
week
tabl
median
time
onset
symptom
hospit
admiss
day
rang
onset
symptom
admiss
intens
care
unit
onset
symptom
death
day
mer
typic
begin
fever
cough
chill
sore
throat
myalgia
arthralgia
follow
dyspnoea
rapid
progress
pneumonia
within
fi
rst
week
often
requir
ventilatori
organ
support
although
patient
symptomat
diseas
present
respiratori
ill
immuno
compromis
patient
present
fever
chill
diarrhoea
later
develop
pneumonia
similar
sar
least
third
patient
mer
gastrointestin
symptom
vomit
diarrhoea
risk
factor
develop
sever
diseas
addit
immunocompromis
state
includ
comorbid
eg
obes
diabet
cardiac
diseas
lung
diseas
concomit
infect
low
albumin
concentr
predictor
sever
ill
age
older
year
associ
mortal
case
seri
saudi
arabia
data
avail
viral
dynam
clinic
cours
suggest
patient
mer
shorter
time
ill
onset
clinic
present
requir
ventilatori
support
patient
sar
tabl
higher
respiratori
tract
viral
load
fi
rst
week
ill
sar
sever
viral
ill
common
laboratori
fi
nding
mer
includ
leucopenia
particularli
lymphopenia
tabl
patient
consumpt
coagulopathi
high
creatinin
lactat
dehydrogenas
liver
enzym
concentr
candida
speci
occur
patient
receiv
invas
mechan
ventil
chest
radiographi
tomographi
fi
nding
mer
consist
viral
pneumon
acut
respiratori
distress
syndrom
bilater
hilar
infi
ltration
unilater
bilater
patchi
densiti
infi
ltrate
segment
lobar
opac
groundglass
opac
small
pleural
eff
usion
case
lower
lobe
gener
aff
ect
upper
lobe
earli
cours
ill
rapid
radiograph
progress
sar
patient
viral
rna
blood
urin
stool
much
lower
viral
load
respiratori
tract
merscov
viral
load
genom
fraction
upper
respiratori
tract
specimen
eg
nasopharyng
swab
lower
lower
respiratori
tract
specimen
tracheal
aspir
bronchoalveolar
lavag
fl
uid
probabl
account
ineffi
cienci
interhuman
transmiss
lower
respiratori
tract
excret
merscov
rna
detect
month
ill
patient
suggest
prolong
shed
could
sourc
spread
outbreak
lower
respiratori
tract
specimen
bronchoalveolar
lavag
fl
uid
sputum
tracheal
aspir
contain
highest
viral
load
collect
whenev
possibl
mer
confi
rmed
detect
viral
nucleic
acid
serolog
presenc
viral
nucleic
acid
confi
rmed
either
posit
realtim
revers
transcript
pcr
least
two
specifi
c
genom
target
singl
posit
target
sequenc
second
posit
pcr
product
avail
realtim
revers
transcript
pcr
test
includ
assay
target
rna
upstream
e
gene
upe
assay
target
open
read
frame
orf
orf
assay
upe
target
highli
sensit
recommend
screen
orf
assay
equal
sensit
orf
assay
less
sensit
use
confi
rmation
assay
shown
crossreact
respiratori
virus
includ
human
coronavirus
two
target
site
merscov
genom
suitabl
sequenc
aid
confi
rmation
rnadepend
rna
polymeras
rdrp
present
orf
n
gene
fi
gure
mer
case
confi
rmed
pcr
serial
sampl
pcr
test
upper
lower
respiratori
tract
bodi
part
eg
serum
urin
stool
recommend
understand
viral
replic
kinet
guid
infect
control
respiratori
sampl
collect
least
everi
day
confi
rm
viral
clearanc
two
consecut
neg
result
obtain
confi
rmation
infect
antibodi
detect
pair
serum
sampl
collect
day
apart
fi
rst
taken
fi
rst
week
ill
posit
screen
assay
elisa
immunofl
uoresc
assay
follow
confi
rmatori
neutralis
assay
singl
sampl
might
also
valuabl
identifi
cation
probabl
case
collect
least
day
onset
symptom
serolog
result
care
interpret
might
confound
crossreact
coronavirus
specifi
c
drug
treatment
exist
mer
support
treatment
mainstay
manag
evidencebas
recommend
treatment
provid
basi
decis
make
clinic
set
panel
merscov
readili
inhibit
type
interferon
especi
cultur
cell
combin
test
sever
ill
patient
show
improv
surviv
day
day
possibl
result
administr
advanc
stage
diseas
sever
drug
inhibit
merscov
cell
cultur
includ
ciclosporin
mycophenol
acid
compound
chloroquin
chlorpromazin
loperamid
lopinavir
inhibit
viru
replic
eff
ectiv
concentr
vitro
although
whether
drug
use
patient
unknown
merscovspecifi
c
peptid
fusion
inhibitor
function
similarli
hiv
drug
enfuvirtid
diminish
viru
replic
cultur
cell
provid
novel
approach
mer
treatment
human
monoclon
neutralis
antibodi
convalesc
sera
recov
patient
might
use
treatment
deliv
time
fashion
exploratori
posthoc
metaanalysi
studi
sar
sever
infl
uenza
show
signifi
cant
reduct
mortal
follow
antibodi
treatment
compar
placebo
treatment
pool
odd
ratio
ci
system
corticosteroid
use
empir
patient
dampen
immunopatholog
host
respons
although
surviv
benefi
report
steroid
use
cautious
use
associ
worsen
outcom
patient
infect
sarscov
epidem
data
need
anim
studi
care
done
clinic
virolog
studi
prioriti
treatment
convalesc
plasma
interferon
ideal
randomis
clinic
trial
suffi
cient
number
patient
avail
present
clinic
manag
patient
sever
diseas
larg
reli
meticul
intens
care
support
prevent
complic
recommend
prevent
mer
avail
us
center
diseas
control
prevent
saudi
ministri
health
main
infect
prevent
control
measur
droplet
precaut
wear
surgic
mask
within
patient
contact
precaut
wear
gown
glove
enter
patient
room
remov
leav
droplet
precaut
ad
standard
precaut
provid
care
patient
sign
acut
respiratori
infect
eye
protect
use
healthcar
worker
care
probabl
confi
rmed
patient
public
health
england
us
center
diseas
control
prevent
saudi
ministri
health
recommend
manag
known
suspect
merscov
infect
includ
use
person
protect
equip
gown
glove
eye
protect
goggl
face
shield
respiratori
protect
equival
fi
ttest
nation
institut
occup
safeti
healthcertifi
ed
dispos
fi
ltere
facepiec
respir
patient
mer
place
neg
pressur
room
room
room
exhaust
fi
ltere
higheffi
cienci
particul
air
fi
lter
airborn
precaut
least
six
air
chang
per
hour
appli
treatment
room
perform
aerosolgener
procedur
recommend
evidencebas
proven
eff
ectiv
hospit
aff
ect
countri
camel
infect
merscov
develop
rhiniti
show
sign
infect
might
shed
viru
nasal
eye
discharg
faec
viru
also
found
raw
milk
infect
camel
merscov
stabl
camel
breast
milk
extend
period
time
thu
pasteuris
cook
recommend
destroy
viru
raw
urin
use
medicin
purpos
sign
diseas
nonspecifi
c
possibl
know
whether
anim
farm
market
race
track
slaughterhous
excret
merscov
without
virolog
test
camel
farm
worker
slaughterhous
worker
market
worker
veterinarian
handl
camel
race
facil
practis
good
person
hygien
includ
frequent
handwash
touch
anim
avoid
touch
eye
nose
mouth
hand
avoid
contact
sick
anim
consider
also
given
wear
protect
gown
glove
handl
anim
especi
camel
sign
upper
respiratori
tract
diseas
saudi
govern
issu
updat
health
guidelin
pilgrim
although
merscov
caus
sever
communityacquir
pneumonia
hospitaladmit
pilgrim
investig
hajj
good
infecti
diseas
surveil
control
measur
essenti
prevent
major
outbreak
mer
mass
gather
nearli
year
sinc
discoveri
merscov
sever
import
question
epidemiolog
rout
transmiss
pathogenesi
treatment
remain
unansw
although
zoonot
sourc
viru
like
rout
transmiss
could
either
direct
indirect
contact
consumpt
contamin
food
food
product
although
sever
studi
shown
possibl
link
human
case
mer
transmiss
camel
much
unknown
origin
geograph
distribut
exact
mode
transmiss
relationship
merscov
merscovlik
infect
bat
camel
anim
human
be
sporad
natur
mani
case
mer
hinder
indepth
casecontrol
studi
investig
rate
secondari
transmiss
includ
establish
role
subclin
infect
humantohuman
transmiss
natur
histori
pathogenesi
host
suscept
factor
virul
viral
kinet
period
greatest
infecti
underli
mechan
protect
immun
factor
govern
treatment
outcom
also
unknown
lack
knowledg
hinder
develop
drug
treatment
adjunct
treatment
specifi
c
diagnost
test
biomark
vaccin
merscov
yet
fulli
adapt
infect
peopl
persontoperson
transmiss
yet
suffi
cientli
effi
cient
pandem
potenti
inform
long
viru
infect
human
be
could
obtain
analys
human
serum
sampl
avail
would
help
assess
likelihood
adapt
peopl
genom
studi
provid
insight
molecular
characterist
mutat
rate
viru
transmiss
dynam
defi
ning
factor
crucial
speci
specifi
citi
virul
enabl
discoveri
new
drug
target
novel
drug
diagnost
test
vaccin
postmortem
histolog
studi
avail
even
limit
autopsi
surgic
specimen
would
use
avail
anim
model
sever
merscov
infect
diseas
import
understand
patho
genesi
natur
histori
immun
respons
develop
eff
ectiv
treatment
studi
urgent
need
coronavirus
high
genet
mutabl
merscov
continu
circul
countri
arabian
peninsula
although
interhuman
transmiss
still
ineffi
cient
health
author
govern
research
commun
prepar
emerg
merscov
increas
capac
transmiss
pandem
potenti
author
contribut
develop
draft
outlin
fi
nalis
seminar
report
compet
interest
